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Abstract
Background
Research using orthotopic and transgenic models of cancer requires imaging methods to
non-invasively quantify tumour burden. As the choice of appropriate imaging modality is
wide-ranging, this study aimed to compare low-field (1T) magnetic resonance imaging
(MRI), a novel and relatively low-cost system, against established preclinical techniques:
bioluminescence imaging (BLI), ultrasound imaging (US), and high-field (9.4T) MRI.
Methods
Amodel of colorectal metastasis to the liver was established in eight mice, which were
imaged with each modality over four weeks post-implantation. Tumour burden was
assessed from manually segmented regions.
Results
All four imaging systems provided sufficient contrast to detect tumours in all of the mice
after two weeks. No significant difference was detected between tumour doubling times esti-
mated by low-field MRI, ultrasound imaging or high-field MRI. A strong correlation was mea-
sured between high-field MRI estimates of tumour burden and all the other modalities (p <
0.001, Pearson).
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Conclusion
These results suggest that both low-field MRI and ultrasound imaging are accurate modali-
ties for characterising the growth of preclinical tumour models.
Introduction
Translation of research in oncology, from basic biology to therapeutic drug strategies, requires
the use of experimental models of disease. Transgenic and orthotopic models are increasingly
used to study a tumour microenvironment that more accurately reflects the growth and clinical
presentation of the disease [1] than in traditional subcutaneous tumour models [2–4]. Whilst
these models have the potential to improve the translation of novel therapeutic strategies, moni-
toring tumour growth and response to therapy is generally not straightforward. In particular,
transgenic models develop tumours spontaneously and over a longer period compared to
implanted orthotopic models, hence a screening method is vital. Tumour sites can be inaccessible
to traditional calliper measurement of tumour volume [5], and invasive methods used to assess
tumour volume require the termination of entire animal groups, which is incompatible with lon-
gitudinal studies and greatly increases the number of animals required. Biomedical imaging is
key to overcoming this limitation [6], and, additionally, facilitates paired statistical analysis from
longitudinal measurements and reduces the required cohort sizes. However, which imaging
modality offers the best and most practical solution is often difficult to determine.
In recent years, small-animal imaging has rapidly evolved and many dedicated platforms
exist [7], including magnetic resonance imaging (MRI), ultrasound imaging (US), x-ray com-
puted tomography (CT), positron emission tomography (PET), single photon emission com-
puted tomography (SPECT), fluorescence imaging (FLI), photoacoustic imaging (PAI) and
bioluminescence imaging (BLI). More recently, low-field, ‘benchtop’ MRI scanners have been
developed, which offer promise for relative low-cost and precise imaging of pre-clinical models
[8–11]. Several of these imaging modalities can also provide functional information on tumour
function and microstructure, such as blood flow [12;13], cell density [14], hypoxia [15] and
metabolite concentration [16], each of which has been used to assess response to anti-cancer
therapy. However, particularly for drug development in cancer, the parameter of greatest inter-
est still tends to be tumour volume. For translational research, measurement of the change in
tumour volume allows direct comparison with the clinical assessment via the RECIST criteria
[17]. Determining pre-therapy tumour volumes of animal models in therapy trials is essential
for group standardisation, alongside the confirmation of successful engraftment.
Measuring tumour volume is generally straightforward and fast, although the imaging
modality that provides the optimal platform, both in terms of scientific and practical consider-
ations, depends on the requirements of a particular study. The accessibility of each small ani-
mal imaging platform will vary between institutions and research groups, and deciding which
systems to use can be complex, and has led to a few studies comparing the application of differ-
ent systems [7;18]. However, only a limited number of studies have directly compared small-
animal MRI and US imaging systems in assessing tumour volumes, though there are some
alternative applications and clinical reports available [19–22]. A key advantage of non-invasive
imaging is its ability to monitor individual animals longitudinally [23;24]. However, the effi-
cacy of novel ‘benchtop’ MRI is currently unreported in this context.
The aim of this study was to assess the ability of a low-field MRI system (field strength 1T)
to longitudinally characterise and quantify the growth of a mouse liver metastatic model whilst
directly comparing its performance to three small-animal imaging platforms: high-field MRI
(field strength 9.4T); bioluminescence imaging (BLI); and ultrasound imaging (US). Of all the
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available modalities, these provide the best potential for assessing tumour burden, without the
use of ionising radiation. We hope that this study may provide useful information for imaging
laboratories planning tumour growth characterisation studies or looking to invest in new imag-
ing equipment.
Imaging Systems Overview
Preclinical MRI is generally performed using high-field systems (4.7T – 11.75T), due to the sig-
nal-to-noise gains that can be achieved with larger magnetic fields. Such imaging systems are
able to characterise both anatomical and functional information across the whole body. How-
ever, high-field systems are expensive, occupy a relatively large area and require routine main-
tenance due to the cryogenic cooling system of the superconducting magnet. Given the ability
of MRI to allow precise and accurate quantification of tumour volume [25], it was considered
the gold-standard for comparison with other techniques in this study.
Recently developed, low-field, permanent-magnet MRI systems have a number of advan-
tages over high field systems such as their relative small footprint [8], and can be situated in
standard biomedical research laboratories. Though the design is compact, it is suitable for in
vivo pre-clinical research with mice and small rats. Such low-field MRI scanners inherently
have lower signal-to-noise characteristics than their high-field counterparts, although the
lower field can also lead to reduced image artefacts [26]. Moreover, shortened longitudinal
relaxation times can reduce image acquisition time and provide greater image contrast [27;28].
Thus, high-field and low-field MRI were treated as different imaging modalities for the purpose
of this study.
BLI is one of the most extensively used technologies for assessing biological function in pre-
clinical models of disease [29;30]. The underlying mechanism of BLI is the enzymatic conver-
sion of luciferin, resulting in the emission of light. The introduction of luciferase genes into
non-expressing cells allows various biological functions to be assessed by the administration of
a luciferin substrate. However, the resultant emitted light is of low intensity, and the scattering
of the light in biological tissue makes quantification difficult. BLI is fast and highly sensitive,
allowing very small numbers (<1000 [31]) of engineered cells to be detected in vivo. As such it
is particularly suited to cell tracking, either of cancerous cells or cells of the immune system, in
a longitudinal, non-invasive manner [32;33]. BLI systems are relatively compact, requiring a
dark box and a sensitive camera for 2D imaging of the emitted light.
US imaging has been employed in preclinical research for several decades. Recent develop-
ment of dedicated US systems with ultra-high frequency transducers (25–70 MHz) has revolu-
tionised preclinical US imaging, allowing high temporal (<1 ms) and spatial (<30 um)
resolution images of heart [34], blood flow, tumour volume [35;36], and embryonic develop-
ment [37,38], each of which can be acquired in real-time and in three dimensions. However,
US imaging is liable to inter-operator variability, and has limited application to imaging
tumours propagated within the brain or bone due to signal attenuation. Preclinical ultrasound
imaging systems are compact, and use a dedicated animal platform for ease of use with the
transducer and stepping motor for 3D imaging. These developments mean that preclinical US
may be a viable alternative to other imaging methods, due to its speed, cost effectiveness and
relative ease of image acquisition.
Methods
Ethics statement
All animal studies were approved by the University College London Biological Services Ethical
Review Committee and licensed under the UK Home Office regulations and the Guidance for
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the Operation of Animals (Scientific Procedures) Act 1986 (Home Office, London, United
Kingdom) and United Kingdom Co-ordinating Committee on Cancer Research Guidelines for
the Welfare and Use of Animals in Cancer Research [39].
Cell line and orthotopic liver tumour xenograft
The human colorectal carcinoma cell line SW1222 was previously engineered in-house to
express the luciferase gene [40]. A model of liver metastases, previously established in-house,
was created in eight female MF1 nu/numice (6–8 weeks old, 25–30 g); defined as day 1. 1 x106
SW1222 luc cells were injected intrasplenically in a Dulbecco’s Modified Eagle’s Medium vehi-
cle (Sigma Aldrich, UK) via sterile surgical procedure so tumour cells washed through to the
liver, where they established solid tumour deposits. Following splenectomy, to remove the pos-
sibility of tumours growing at the spleen, the laparotomy rectus sheath incision was sutured
(Ethicon, Johnson & Johnson, USA) and the skin was closed with wound clips (Autoclip sys-
tem, Harvard Apparatus, UK).
The mice were then monitored for development of solid tumour deposits via biolumines-
cence imaging, ultrasound imaging, low-field (1T) MRI and high-field (9.4T) MRI. Mice were
allowed to recover for 24 hours between imaging sessions, in accordance with local regulations.
US and BLI imaging were performed on the same day where possible; due to the proximity and
efficiency of the systems, mice were kept anesthetised between the acquisitions. BLI and US
imaging started at day 2. As the tumours were not expected to grow to a size detectable by the
resolution of the high- and low-field MRI in the first week, these modalities began from day 7.
For all imaging, mice were anesthetised with 4% isoflurane in 1 L/min O2, and then main-
tained at 1.5% isoflurane using nose-cones within the imaging systems. Animals were moni-
tored daily, mice that presented a tumour burden greater than 50% of the total liver volume
were sacrificed by cervical dislocation, in accordance with the local regulations.
Bioluminescence Imaging
BLI was performed on days 2, 9, 20 and 23 using a Photon Imager Optima (Biospace Lab,
France). For whole body in vivo images, animals were administered 150 μL D-luciferin (Bio-
synth, USA) intraperitoneally at 150 mg/kg. Four mice were imaged simultaneously per acqui-
sition. Peak emission had previously been determined to be at approximately 15 minutes post-
injection, so animals were anaesthetised at 12 minutes and placed within the imaging chamber.
Images were acquired in a single, supine orientation, with a 10 s exposure time.
High-field (9.4T) MRI
High-field imaging was carried out on days 8, 14, 20 and 27 on an Agilent 9.4T horizontal-bore
VNMRS scanner (Agilent Technologies, Santa Clara, USA) using a 39 mm diameter birdcage
coil (RAPID Biomed, Rimpar, Germany). Animals were placed supine within a custom-built
cradle. Core temperature was monitored with a rectal temperature probe, and maintained
using heated water pipes. Respiratory rate was monitored using respiratory bellows, which
were also used to gate the image acquisition (SA Instruments, NY, USA). Animals were then
positioned within the scanner and a gated, manual shim was carried out over the entire liver
volume.
Entire liver volumes were acquired with a respiratory triggered, multi-slice fast spin-echo
sequence, typically using 30–35 slices. Sequence parameters included: in-plane resolution 0.156
x 0.156 mm2; slice thickness, 0.75 mm; effective echo time (TE), 19 ms; repetition time (TR),
1 s; 2 averages; total acquisition time was 9 minutes. These parameter values were chosen on
the basis of previous in-house measurements of tumour and liver longitudinal (T1) and
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transverse (T2) relaxation times at 9.4T (Liver T1 = 1345 ± 280 ms and T2 = 18 ± 6 ms; tumour
T1 = 2236 ± 544 ms and T2 = 35 ± 8 ms), which were used to numerically optimise the contrast
between each tissue type [41]. These relaxation times are in good agreement with previous
excised tissue measurements in colon carcinoma metastases at 9.4T [42].
Benchtop, low-field (1T) MRI
Low-field MRI was performed on days 7, 15, 18, 23 and 28 on a Bruker 1T ICON (Bruker Bio-
Sciences Corporation, Ettlingen, Germany) using a 30 mm diameter solenoid coil. As men-
tioned above, the practical differences between low- and high-field MRI required that they
were treated as different imaging modalities. However, the image resolution of low-field MRI
was matched to those acquired on the high-field MRI scanner, and scan duration was limited
to below 30 minutes. Animals were anesthetised and positioned prone within a holding cradle:
physiological monitoring was provided via a rectal thermometer and respiratory bellows (SA
Instruments, New York, USA), the temperature was maintained via a water-heated cradle.
Once the animal was positioned within the scanner, automated power calibration and shim-
ming were performed prior to pilot imaging.
Whole liver anatomical data were acquired using a respiratory-triggered, multi-slice fast
spin echo. The datasets were resolution-matched to the high-field data, and acquired with the
following parameters: effective TE, 25 ms; TR, 2s; 3 averages; total acquisition time, 25 minutes.
As with the acquisition at 9.4T, these parameter values were chosen on the basis of a numerical
optimisation that used the following relaxation times, which were characterised previously in-
house: liver T1 = 310 ± 87 ms, T2 = 56 ± 34 ms; tumour T1 = 505 ± 278 ms, T2 = 78 ± 28 ms
[41].
Ultrasound Imaging
US imaging was performed on days 2, 9, 16 and 23 with a Vevo 2100 system (VisualSonics,
Toronto, Canada) with an MS550D transducer. Mice were anaesthetised and placed supine on
the handling table, where ECG and respiration were monitored using conductive strips built in
to the imaging platform. The temperature was maintained using a heating lamp and monitored
using a rectal probe. The abdomen of each mouse was covered with warmed acoustic coupling
jelly. The transducer was placed in a sagittal orientation and a stepper motor was used to
acquire a three-dimensional data set (resolution of 0.018 x 0.018 x 0.076 mm3) across the
whole liver, using respiratory gating; total scan time of approximately 5 minutes.
Image Segmentation
The mean photon flux from the BLI data was calculated over an automated region of interest
(ROI) using M3Vision software (Biospace Lab, France). All data sets acquired with US, low-
field MRI and high-field MRI were manually segmented into tumour and normal liver tissue
by two researchers with at least four years of preclinical imaging experience, using Amira 5.4
(FEI, Oregon, USA). Segmentation was performed blind, following randomisation of the day
and mouse number.
Whole liver volumes from low- and high-field MRI data were analysed. However, whole
liver analysis wasn’t practically feasible for US images: the three-dimensional acquisition pro-
vided a very fine step thickness, and sagittal coverage of the whole liver typically yielded in
excess of 250 slices. To enable segmentation within a reasonable timeframe, the data were com-
pressed such that every three slices were averaged into one to yield a final slice thickness of
0.228 mm. In order to match the number of slices segmented by MRI, three representative
samples of ten consecutive slices were chosen by each user, to account for heterogeneity of
Multimodal Imaging Comparison of an Orthotopic Liver Tumour Model
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tumour engraftment. The relative tumour burden was resultantly used to compare the MRI
and US for analysis of model development, calculated as the ratio of observed tumour to
observed liver volume:
tumour burden ¼ tumour volume
liver volume
 100%: Equation 1
Quantitative Comparison of Modalities
Tumour doubling time. Doubling times for tumour growth were estimated by fitting an
exponential function of the form V = V0 exp(Rt) to estimates of tumour burden V (from Eq 1),
as a function of time t. A linear-least squares algorithm in MATLAB (MathWorks, Natick,
MA, USA) was used to estimate the rate constant R, and the doubling time τ was then given by
τ = ln(2)/R. Tumour burden and flux were fitted for each mouse and for each modality, using
data from day 9 to day 23, thus the same group size (n = 8) was maintained for all modalities.
Day 2 BLI data was excluded from this analysis, as the signal included non-engrafted tumour
cells.
Variability of intra-user and inter-user tumour burden assessment. The coefficient of
variability was used to assess intra- and inter-user variability of segmentation for the US, low-
and high-field MRI:
CV ¼ s
m
 100%; Equation 2
Where σ is the standard deviation and μ is the mean. Five duplicate datasets were included
within both user’s blinded segmentation, allowing intra-user variability (CVU) and inter-user
variability (CVA) to be calculated. CVU measures the user’s repeatability in assessing the data,
and the CVA gives the estimate of agreement between user segmentation of matching data. A
separate dataset was performed blind in a given region to remove the possibility of user choice
of analysed slices contributing to the variation in the US data.
Contrast to noise ratio estimation. The ability to discern tumour from normal liver is
dependent on the difference in signal from the two tissue types and how this compares to the
noise variance inherent in the data. The contrast-to-noise ratio (CNR) for MRI and US was cal-
culated by defining two regions corresponding to tumour or normal-appearing liver. The mean
(μL, μT) and standard deviation (σL, σT) of the signal within each region were then used in the
following equation:
CNR ¼ jmL  mT jﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sL2  sT 2
p : Equation 3
For an approximation of the signal-to-noise of the BLI, the mean signal of each tumour was
normalised by the mean signal of a noise ROI drawn distal from the mice. As the mice were
imaged in two sets of four, an ROI was drawn for each image at every week. The SNR was then
calculated for the entire cohort over all the imaging time points.
Sensitivity calculation. A sensitivity measure was used to quantify the ability of each
modality to detect tumours within the liver, compared with high-field MRI, taken as the gold-
standard. Data sets from all time points and from each modality were denoted as either exhibit-
ing tumours, or devoid of tumours. Sensitivity (S) at weeks 2–4, for low-field MRI and US, was
calculated using: S = TP(TP + FN), using the high-field MRI data to determine true positives
(TP) and false negatives (FN).
Multimodal Imaging Comparison of an Orthotopic Liver Tumour Model
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Statistical analysis. All statistical analysis was performed using MATLAB (MathWorks,
USA). ANOVA was used in order to compare group-wise doubling times, choosing time points
which ensure a consistent group size of eight. Pearson’s linear correlation was used to compare
between the modalities estimation of tumour burden within the smallest period between imag-
ing, omitting 0% burden values from all correlation calculations: high-field MRI (day 8, day
20) vs. BLI (day 9, day 20), high-field MRI (day 8, day 14, day 20, day 27) vs. low-field MRI
(day 7, day 15, day 21, day 28), high-field MRI (day 8, day 14, day 20) vs. US (day 9, day 16,
day 23).
Results
Three mice were removed from the study at day 24 due to excessive tumour burden. All other
mice (n = 5) remained in the study until the final time point at day 28.
Fig 1 shows example images of the development of liver metastases in a mouse from BLI,
high-field MRI, low-field MRI and ultrasound imaging with the corresponding three-dimen-
sional visualisations over three weeks of imaging. BLI signal was detected in the region of the
liver at day 2 in all mice (n = 8), and in the same region at all further time points, demonstrat-
ing successful engraftment of the liver tumour model in all mice. Due to the dynamic range
over the weeks, the background signal in the final time-point has been amplified such that the
BLI signal appears clipped at the location of the partitions between the mice when imaging
multiple animals.
For the US, high and low-field MRI, the liver has been outlined (red dash), example tumours
have been demarcated by an orange arrow, and example vasculature has been delineated with a
white arrow. In the 3D visualisations, the liver volume has been rendered in red and the seg-
mented tumours as yellow. Liver metastases increased in volume with time in all mice, starting
as small, localised deposits often located at the periphery of the liver.
In the high-field (9.4T) MRI images, tumours appeared bright relative to the normal liver
and blood vessels were dark. Images from low-field (1T) MRI were similar to high-field images,
but with observably lower signal-to-noise characteristics, although tumours could still be dis-
cerned from liver. Some artefacts due to respiratory motion were evident (star), as shown in
Fig 1. In US images, tumours appear hypo-intense relative to liver tissue and vasculature more
so. Transmission shadowing caused by the ribs (star), was found to obscure some regions of
the liver.
The change in the log bioluminescence flux is shown in Fig 2A for all animals, in which the
signal appears to plateau after 20 days. In four mice, signal intensity decreased at day 9, due to
the presence of viable tumour cells at day 2 that did not immediately engraft. The individual
growth curves of estimated tumour burden from high-field MRI data are shown in Fig 2B,
which reveal substantial variability in tumour growth between animals. Mouse 1 and Mouse 6
exhibited a small tumour burden, which appears to plateau, which is also consistent with their
associated low BLI flux.
For comparison, the mean growth curves for high-field MRI, low-field MRI and US are
shown in Fig 2C. A close relation can be seen across the modalities; the apparent plateau of
tumour burden in the high-field MRI is due to the removal of three animals with an excessively
large tumour burden, prior to the final time point. This ‘plateau’ effect was not observed in 1T
MRI data, as it underestimated the tumour burden prior to the removal of these mice, and the
US imaging stopped before these mice were removed. No significant difference (p> 0.2,
ANOVA) was measured between tumour volume doubling times (Fig 2D) estimated by high-
field MRI (2.9 ± 1.1 days, mean ± standard deviation), US (3.0 ± 1.5 days) and low-field MRI
Multimodal Imaging Comparison of an Orthotopic Liver Tumour Model
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Fig 1. Representative images of the liver in a mousemodel of colorectal metastasis, acquired over all
time points, for all four modalities. Bioluminescence images (photon flux measured in p/s/cm2/str) have
been scaled by the same logarithmic range across all time points. Bioluminescent signal can be seen at the
location of the liver, which increases with the onset of the tumours. For US, high- and low-field MRI, typical
slices are shown above corresponding three-dimensional visualisations of a manually segmented liver (red)
and tumours (yellow). In the raw images, liver tissue has been delineated by a dashed red line, example
tumours have been marked with orange arrows and example blood vessels are shown with a white arrow.
Image artefacts have been demarcated with an orange star; signal loss occurs in MRI data due to cardiac
motion, and ultrasound images suffer from transmission loss due to the ribs.
doi:10.1371/journal.pone.0156162.g001
Multimodal Imaging Comparison of an Orthotopic Liver Tumour Model
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(1.7 ± 0.6 days). The average doubling time estimated from BLI photon-flux was significantly
longer, (5.8 ± 0.6 days, p> 0.01, ANOVA).
Correlating BLI photon flux with high-field MRI estimates of tumour burden from the
same time points (Fig 3A) showed a strong correlation (r2 = 0.98, p< 0.001, Pearson’s).
Tumour burden measured by US (Fig 3B) was significantly correlated with estimates from
high-field MRI (r2 = 0.84, p< 0.001, Pearson’s), as was tumour burden from low-field MRI
(Fig 3C) (r2 = 0.89, p< 0.001, Pearson’s).
Measurements of the sensitivity of US and low-field MRI to detect tumours, compared to
high-field (9.4T) MRI as a gold standard, revealed that both modalities were able to detect
tumours by the week 3, though US was more sensitive at this time (Fig 3D). The two techniques
were equally sensitive by week 4.
Table 1 shows a summary of the imaging parameters used for this study, and the results of
the quantitative comparisons between the modalities. The experiment times are calculated
from an approximate average time in minutes taken per mouse to set-up and acquire whole
liver images. This was lowest for the BLI system, which has the potential to acquire data in five
mice simultaneously, thereby offering a very high-throughput platform (4 minutes per mouse).
The next fastest platform was US (10 minutes per mouse), followed by high-field MRI (20 min-
utes per mouse) and low-field MRI (40 minutes per mouse). The US procedure was shortened
in this study with the use of nude mice, which did not require fur to be removed. The contrast-
to-noise ratio (CNR) between tumour and liver tissue was greatest in high-field MRI data
(4.9 ± 1.4, mean ± standard deviation), followed by low-field MRI (2.5 ± 0.9), and US
(0.4 ± 0.1). Due to the specific nature of the BLI signal, the signal is only detected from tumour
Fig 2. Multimodal assessment of tumour growth: (a) Individual tumour log-growth curves from BLI photon
intensity across the whole study. Photon flux increased a hundred-fold between day 9 and day 20 and then
plateaued. (b) Assessment of tumour burden, characterised by high-field MRI, in each mouse (M1, M2, M3,
etc.). A large spread of tumour volumes was observed over the course of the study. (c) From group-wise plots
(mean ± standard deviation) of tumour burden, a good agreement can be seen between US, high-field MRI
and low-field MRI estimates of tumour burden. (d) Box-and-whisker plots representing measurements of
tumour volume doubling times for the group, across all modalities. ANOVA analysis indicated no significant
differences (p > 0.2) between the US, low- and high-field MRI estimates of tumour burden, but a significant
overestimation (p < 0.01) for BLI.
doi:10.1371/journal.pone.0156162.g002
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cells, thus contrast to liver tissue is not a comparable parameter, and hence not included in to
Table 1. Placing a ROI distal from any mice at each week, a signal-to-noise of the BLI was esti-
mated to be 1114 ± 947 (mean ± standard deviation); the large variance is due to the large
spread of tumour uptake within the cohort, however the tumour signal was far greater than the
background noise.
Data acquired with high-field MRI, proposed as the gold-standard in this study, produced
the smallest intra-user (CVU) and inter-user (CVA) variability during segmentation; these mea-
sures for low-field MRI and US segmentations were similar, most likely reflecting the trade-off
between the CNR and resolution associated with each modality.
Fig 3. Correlation plots of tumour burden measured by high-field (9.4T) MRI (matched within three days) and each of the other modalities:
(a) BLI r2 = 0.98, (b) US r2 = 0.84, (c) low-field (1T) MRI r2 = 0.89 (p < 0.001, Pearson’s, for all modalities). (d) The sensitivity of low-field
MRI and US to detect tumours in the liver, using high-field MRI as a gold-standard.
doi:10.1371/journal.pone.0156162.g003
Multimodal Imaging Comparison of an Orthotopic Liver Tumour Model
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Discussion
Pre-clinical, low-field (1T) MRI has not previously been assessed for its suitability to image
liver tumour volumes, and was here evaluated alongside high-field (9.4T) MRI, ultrasound
imaging (US) and bioluminescence (BLI). When comparing different technologies, a challenge
exists to find a robust gold-standard to provide a set of data that is as close to a ground truth as
possible. For the current study, in which the ability of several small animal imaging platforms
to detect tumours and quantify their volume was evaluated in a mouse model of colorectal liver
metastasis, high-field MRI was chosen as the gold-standard, and yielded the smallest variations
in user assessment.
MRI signal increases with magnetic field, which is reflected in the reduced experimental
time and greater CNR measured in this study with high-field MRI compared with low-field
MRI. Though a good correlation was observed between the low-field and high-field MRI, the
low-field MRI estimation of tumour doubling time was non-significantly shorter compared to
the high-field MRI and US, suggesting a reduced sensitivity of the low-field MRI to the pres-
ence of smaller metastases. A non-significant, but consistent underestimation was observed in
measurements of tumour burden by low-field MRI, largely due to the difficulty in distinguish-
ing the inferior liver from the intestines with the acquired contrast: a 12% overestimation of
liver volume was measured with the low-field MRI (data not shown), where the absolute
tumour volumes were not significantly different, suggesting that measurements of absolute vol-
ume may be more suitable for the benchtop system.
The slice thickness of the US data was compressed by a factor of three to one, rather than
matched to the slice thickness of the MRI data, in order to maintain the advantage of the fine
step resolution offered by the 3D imaging. For a full quantification of tumour volume, manual
segmentation is required, which can be time-consuming, although automated segmentation
approaches can be developed for both this and MRI data [43]. However, though representative
sampling of the US data covered approximately 25% of the whole liver volume, this method
proved to be efficient and showed a strong correlation with tumour burden over the whole
liver assessed by high-field MRI. More localised 3D imaging and whole volume analysis would
be feasible for single-tumour models.
Individual BLI log flux growths exhibited a similar trend and produced a small variation in
doubling time, suggestive that this technique is not sensitive to the variability in tumour bur-
den. The significant overestimation in the doubling time measured in the BLI is likely to be due
to the log flux signal plateau curve and may be better characterised by increasing the number
of acquisitions earlier on in the study. In addition, a sigmoid function may be a better fit than a
Table 1. Comparison of experimental parameters and derived properties across the modalities.
Exp. Time (min) Resolution (mm) CNR CVU (%) CVA (%) Doubling Time (days)
BLI 4 n/a n/a n/a n/a 5.8 ± 0.6
9.4T MRI 20 0.15 x 0.15 x 0.75 4.9 4.7 7 2.9 ± 1.1
1T MRI 40 0.15 x 0.15 x 0.75 2.5 11.1 13.3 1.7 ± 0.6
US 10 0.018 x 0.018 x 0.076 0.4 14.3 9.9 3.0 ± 1.5
Experiment time (Exp. Time) is an approximate throughput time per mouse, including set-up and images acquisition, using the most efﬁcient application of
the protocols in this study. The image resolution in this table is that used in this study, and not the limit of the system. Contrast-to-noise ratio (CNR) was
estimated using Eq 3, and describes the contrast between normal liver and tumour tissue in this study. The coefﬁcients of intra-user (CVU) and inter-user
(CVA) variability were calculated from Eq 2, and describe the reproducibility of tumour volume estimates, from image segmentation, for each modality. The
ﬁnal column shows the tumour volume doubling time (mean ± standard deviation) estimated from each modality.
doi:10.1371/journal.pone.0156162.t001
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simple exponential, although this prevents straightforward comparison between modalities
[44]. A limitation of the BLI in this study is that only one projection of the light emission was
acquired, whereas a ‘tomographic’ approach may be more suitable to assess tumour burden
and distribution [45]. Nonetheless, a strong correlation was observed between high-field MRI
tumour burden estimates and BLI photon flux and could potentially be used to define a calibra-
tion curve for future studies, though this will require extensive characterisation for each model,
cell line and system. Estimates of tumour burden, relative to normal liver, is likely to be closely
linked to absolute tumour volume, which is demonstrated by the strong correlation between
tumour burden fromMRI and BLI signal, concurrent with previous studies [46].
The disadvantage of the BLI system is that it requires Luciferin to produce the light, whereas
the other modalities used in this study did not require injected contrasts. The CNR of the MRI
data could potentially be improved with the use of Gadolinium-based contrast agents, which
may also shorten the acquisition time, though will require repeated intra-venous or intra-peri-
toneal administration.
A limitation of this study was that the sensitivity of the imaging modalities to measure
tumour burden changes due to a therapy was not investigated. However, using the coefficients
of variations reported here, future studies can be designed accordingly: to best appreciate the
estimated coefficients of variation, they can be input into a two-sample, two-sided equality
power calculation to predict each modalities utility in assessing tumour shrinkage following
therapy. To measure a 10% change the high-field MRI, low-field MRI and ultrasound imaging
will respectively require 4, 20 and 33 animals, using the intra-user CVs, a power of 80% and 5%
type I error and assuming no significant contrast changes. Furthermore, studies that have mea-
sured on the variability of calliper estimations of tumour volume report CVs between 12–35%,
and generally more varied than imaging such MRI, US and CT [5;22;35;47]. Thus calliper mea-
surements, would mostly yield even larger required groups from power calculations than
imaging.
A key parameter when evaluating the ability of each modality to detect tumours is the mini-
mum tumour size that can be detected. This is primarily limited by the resolution of each of
the imaging modality, alongside its signal-to-noise and contrast-to-noise characteristics. BLI
was able to detect the presence of micro-metastases beyond the resolution of the MRI acquisi-
tion and sub-palpable volumes: viable cells within the liver at day 2, and successfully engrafted
“micro-metastases” at day 9. For both MRI techniques used in this study, voxel volume was
approximately 0.017 mm3, which is typical for preclinical MRI. This could be made smaller,
but with the compromise of decreased signal-to-noise or increased imaging time, and the
parameters used in this study aimed to provide a compromise between both of these factors.
There is currently limited literature comparing US and MRI in application to pre-clinical
tumour volumes, and a strong correlation was measured here between tumour burden estima-
tions of high-field MRI and US. The results of the sensitivity analysis showed that US (pixel
resolution approximately 7 x10-5 mm3) was more sensitive than low-field MRI. As such, US
offers a particularly attractive, low-cost, and rapid platform for tumour burden assessment,
even in the presence of artefacts such as rib shadowing, which may obscure tumours in the
superior liver.
Although available, X-ray CT and nuclear imaging were not incorporated into this study.
This was principally due to the limited number of scanning time points that could be per-
formed, but also to avoid the use of modalities that require ionising radiation, particularly as
there is some evidence that repeated exposure may impact on tumour growth [47].
An interesting observation was the variability found in doubling times associated with the
growth of tumours in the liver, which, according to measurements with high-field MRI, varied
between 1.7 and 4.4 days. This is consistent with results obtained from orthotopic liver
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metastasis models derived from other colorectal cancer cell lines [36;48;49], which reflect a
more variable doubling time in orthotopic tumours than traditional ectopic models, also con-
sistent with investigations of SW1222 metastases [50], though this does not report growth
rates. In addition, a similar growth rate has been reported in subcutaneous models of SW1222
tumours; between 3 and 5 days [51;52], though xenograft models will typically grow to larger
volumes. If a target tumour burden is defined as that at which a therapy study is to be initiated,
this can introduce a significant source of variability, highlighting a key need for imaging when
using orthotopic tumour xenograft models to evaluate novel therapies.
Conclusion
Translational cancer research using orthotopic and transgenic models requires the non-inva-
sive characterisation of tumour volume. Benchtop MRI has not been extensively reported in its
utility, and here demonstrated that low-field MRI is an accurate, low cost method relative to
high-field MRI and could offer straightforward application to tumour growth and potentially
shrinkage measurements. Each of the comparison imaging modalities investigated in this study
offer a complex array of advantages and challenges, thus it isn’t clear which technique is ‘best’
for assessing the presence of tumours and quantifying their volume. Such decisions will depend
on the practical and scientific requirements of individual studies and will, we hope, be guided
by the data presented in this study.
A combination of the applied modalities may provide the most complimentary data for
assessing tumour models: BLI offers a highly specific and efficient method to screen for suc-
cessful tumour engraftment and spread, where the other imaging modalities can then later be
used for precise volumetric imaging. Such a workflow would be particularly advantageous for
spontaneous transgenic models developed for optical imaging. A key observation from this
study was the range of growth rates observed in the metastasis model was identified using each
of the imaging modalities, suggesting that novel low field MRI and high-resolution US are suit-
able for characterising a range of liver tumour volumes.
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